Open label dose escalation ph[ase]. I trial of MK-0646 [etoricoxib] given as a one to two hour every other week infusion in patients with relapsed or refractory locally advanced or metastatic cancers

Trial Profile

Open label dose escalation ph[ase]. I trial of MK-0646 [etoricoxib] given as a one to two hour every other week infusion in patients with relapsed or refractory locally advanced or metastatic cancers

Not stated
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2007

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top